Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 5991 (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

    • Most Recent Events

    • 15 Jun 2023 Results ( As of April 26, 2022, n=78) assessing the safety, tolerability, pharmacokinetics (PK), and antitumor activity ofAZD5991 monotherapy and in combination with venetoclax in patients (pts) with relapsed or refractory (R/R) hematologic malignancies presented at the 28th Congress of the European Haematology Association
    • 25 Aug 2022 Status changed from suspended to discontinued.
    • 14 Feb 2022 Planned End Date changed from 24 Jun 2024 to 4 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top